申请人:Hoffmann-La Roche Inc.
公开号:US05324747A1
公开(公告)日:1994-06-28
Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, n, m, o, p and q are as hereinafter set forth, and, when R.sub.2 is hydrogen, pharmaceutically acceptable salts thereof with bases, are described. The compounds of formula 1 are potent inhibitors of phospholipases A.sub.2 (PLA.sub.2 's) and are therefore useful in the treatment of inflammatory diseases, such as psosiasis, inflammatory bowel disease, asthma, allergy, arthritis, dermatitis, gout, pulmonary disease, myocardial ischemia/reperfusion, and trauma induced inflammation, such as spinal cord injury.
本文描述了具有以下结构式的化合物##STR1## 其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、R.sub.6、R.sub.7、R.sub.8、n、m、o、p和q如下所述,以及当R.sub.2为氢时,它们与碱形成的药用可接受的盐。公式1的化合物是磷脂酶A.sub.2(PLA.sub.2's)的有效抑制剂,因此在治疗炎症性疾病方面非常有用,例如银屑病、炎症性肠病、哮喘、过敏、关节炎、皮炎、痛风、肺部疾病、心肌缺血/再灌注以及创伤诱导的炎症,如脊髓损伤。